Document Detail

Barriers for retinal gene therapy: separating fact from fiction.
MedLine Citation:
PMID:  18565565     Owner:  NLM     Status:  MEDLINE    
The majority of recent preclinical gene therapy studies targeting the retina have used adeno-associated virus (AAV) as the gene transfer vector. However, AAV has several limitations including the ability to generate innate inflammatory responses, the ability to cause insertional mutagenesis at a frequency of up to 56% in some tissues and a limited cloning capacity of 4.8Kb. Furthermore, AAV is known to generate limiting immune responses in humans despite the absence of similar immune responses in preclinical canine and murine studies. Three clinical trials to treat Leber's congenital amaurosis using AAV are under way. A clinical trial to treat Stargardt's using lentivirus vectors has also been recently announced. However, very limited evidence currently exists that lentivirus vectors can efficiently transduce photoreceptor cells. In contrast, very few preclinical ocular gene therapy studies have utilized adenovirus as the gene therapy vector. Nonetheless, the only two ocular gene therapy clinical trials performed to date have each used adenovirus as the vector and more significantly, in these published trials there has been no observed serious adverse event. These trials appear to be poised for Phase II/III status. Activation of cytotoxic T lymphocytes limits duration of transgene expression in the retina from first generation adenovirus vectors. However, an advanced class of adenovirus vectors referred to as Helper-dependent Adenovirus (Hd-Ad) have recently been shown to be capable of expressing transgenes in ocular tissues for more than one year. Hd-Ad vectors have many properties that potentially warrant their inclusion in the retinal gene therapy toolbox for the treatment of retinal degenerative diseases.
Rajendra Kumar-Singh
Related Documents :
18385765 - Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
15515115 - Myocardial gene transfer and long-term expression following intracoronary delivery of a...
12692595 - Coexpression of p21(waf1/cip1) in adenovirus vector transfected human primary hepatocyt...
16415025 - Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, a...
18053775 - Spatial and temporal expression of zimp7 and zimp10 pias-like proteins in the developin...
3058275 - Effect of dna supercoiling and catabolite repression on the expression of the teta gene...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2008-06-18
Journal Detail:
Title:  Vision research     Volume:  48     ISSN:  0042-6989     ISO Abbreviation:  Vision Res.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-14     Completed Date:  2010-06-07     Revised Date:  2014-09-15    
Medline Journal Info:
Nlm Unique ID:  0417402     Medline TA:  Vision Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  1671-80     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dependovirus / genetics
Disease Models, Animal
Gene Transfer Techniques
Genetic Therapy / methods*
Genetic Vectors
Mutagenesis, Insertional
Retinal Degeneration / therapy*
Grant Support
EY 013887/EY/NEI NIH HHS; EY 014991/EY/NEI NIH HHS; R01 EY013837/EY/NEI NIH HHS; R01 EY013837-04/EY/NEI NIH HHS; R01 EY014991/EY/NEI NIH HHS; R01 EY014991-04/EY/NEI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of mutant human Ki-ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its d...
Next Document:  Uptake and depuration of anatoxin-a by the mussel Mytilus galloprovincialis (Lamarck, 1819) under la...